[CASE-STUDY] Sweet Syndrome Associated With Crohn’s Disease Developed After a Combo Therapy With Infliximab and Azathioprine: A Case Report, DEC 2021.
Sweet's syndrome (SS) can develop secondary to inflammatory bowel disease, Crohn's disease and ulcerative colitis. In order to resolve or manage the SS, you have to bring the underlying condition under control.
- "Less than 50 cases of Crohn’s-associated Sweet syndrome have been reported in the published literature."
- "Sweet syndrome can be drug-induced. Granulocyte-colony stimulating factor (G-CSF), antibiotics (norfloxacin, trimethoprim-sulfamethoxazole), antihypertensives (furosemide), non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressives (AZATHIOPRINE), anti-cancer drugs, and antipsychotics are the most commonly related drug categories."
- "Two years after the diagnosis of Crohn’s disease the patient was administered a combo therapy with Infliximab and Azathioprine followed by deep remission. A few months later the patient manifested with skin lesions with histopathological findings suggestive of Sweet syndrome."
- In this case, steroids didn't work, despite being the commonest treatment for SS, and a treatment for Crohn's (used to induce remission). Patient responded well to interleukin inhibitor (anti IL-12, IL-23), ustekinumab (Stelara). It targets the two proteins IL-12 and IL-23, which are produced in the body to help fight infections by temporarily causing inflammation. IL-12 and IL-23 are increased in inflammatory bowel disease, and contribute to ongoing inflammation in the digestive system. Ustekinumab binds to both IL-12 and IL-23 which prevents them from working, helping to relieve inflammation and symptoms. ncbi.nlm.nih.gov/pmc/articl...
